Alexandre Zanghellini is Founder and Chief Executive Officer at Arzeda. In this capacity, he leads Arzeda’s technology and product development and has raised $20M of dilutive and non-dilutive funding to support the company. Alex is the original author of Rosetta academic enzyme design module, and Arzeda’s Archytas™. He also directed the development of Scylax™, Arzeda’s computational metabolic pathway design software. Alex is a keen believer in the power of synthetic biology to solve some of our biggest societal challenges, especially that of transforming industrial processes to be more efficient, sustainable and environmentally friendly.
Before founding Arzeda, Alex held positions in R&D both in academia and industry (Cellectis, NASDAQ: CLLS). He has been directing research in both computational biology and experimental biochemistry as a PI on 4 NSF, USDA and DARPA grants. He is the author of 9 peer-reviewed publications, including in Science and Nature, and is an inventor on 28 issued patents and applications. Alex holds a Ph.D. in biochemistry and biophysics from the University of Washington in Seattle WA, a M. Eng. in computer engineering from ENSTA in Paris, France and a M.S in computer science & machine learning from University Pierre et Marie Curie in Paris, France.